Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour mutational burden and survival with molecularly matched therapy.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2023

de Bortoli Till, Benary Manuela, Horak Peter, Lamping Mario, Stintzing Sebastian, Tinhofer Ingeborg, Leyvraz Serge, Schäfer Reinhold, Klauschen Frederick, Keller Ulrich, Stenzinger Albrecht, Fröhling Stefan, Kurzrock Razelle, Keilholz Ulrich, Rieke Damian T, Jelas Ivan

Abstract excerpt

BACKGROUND: The impact of tumour mutational burden (TMB) on outcome with molecularly matched therapy is unknown. Higher TMB could predict resistance to molecularly matched therapy through co-occurring driver mutations. METHODS: One hundred and four patients with advanced cancers underwent molecular profiling in the DKTK-MASTER program. Fifty-five patients received systemic therapy excluding immunotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Share to Progression-Free Survival

Source

Identifiers

PMID: 37544709
DOI: 10.1016/j.ejca.2023.05.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour mutational burden and survival with molecularly matched therapy.PMID 37544709Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read ↗

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.Semantic proximity Read ↗

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read ↗

Tumour mutational burden: clinical utility, challenges and emerging improvements.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.